Vanguard Group Inc. Sells 381,665 Shares of DexCom, Inc. $DXCM

Vanguard Group Inc. lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 49,074,378 shares of the medical device company’s stock after selling 381,665 shares during the period. Vanguard Group Inc. owned about 0.13% of DexCom worth $3,257,066,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Holocene Advisors LP acquired a new stake in DexCom in the 3rd quarter valued at about $163,964,000. CIBC Private Wealth Group LLC raised its stake in shares of DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after acquiring an additional 2,294,709 shares during the last quarter. DSM Capital Partners LLC lifted its position in shares of DexCom by 76.5% during the third quarter. DSM Capital Partners LLC now owns 2,533,539 shares of the medical device company’s stock worth $170,482,000 after purchasing an additional 1,098,243 shares in the last quarter. Iron Triangle Partners LP acquired a new position in shares of DexCom during the third quarter worth approximately $57,196,000. Finally, DNB Asset Management AS grew its stake in shares of DexCom by 271.8% during the third quarter. DNB Asset Management AS now owns 1,098,544 shares of the medical device company’s stock valued at $73,921,000 after purchasing an additional 803,086 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 3.4%

DexCom stock opened at $59.31 on Wednesday. The company’s 50 day simple moving average is $66.43 and its 200 day simple moving average is $66.51. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The firm has a market capitalization of $22.89 billion, a price-to-earnings ratio of 28.24, a PEG ratio of 1.20 and a beta of 1.55. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 earnings per share. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DXCM shares. Truist Financial reissued a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Barclays reiterated an “underweight” rating and issued a $72.00 price objective (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a research note on Tuesday, March 24th. Piper Sandler restated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Finally, Wells Fargo & Company dropped their target price on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.50.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.